Nevada Leads The Way For Veterinarians To Treat Pets With CBD

Starting this October, veterinarians licensed in Nevada can recommend and administer hemp and cannabidiol products containing not more than 0.3% tetrahydrocannabinol without fear of sanction from the state licensing board.

Earlier this year, Gov. Steve Sisolak signed Assembly Bill 101, making Nevada the first state to legalize the use of cannabinoids as a veterinary treatment. The Nevada Board of Veterinary Medical Examiners helped write AB 101, which the Nevada VMA supported, according to NVMA Executive Director Michelle Wagner.

The bill’s sponsor, State Assemblyman Steve Yeager, introduced the measure in February because Nevada law was unclear about whether veterinarians were permitted to administer CBD products or discuss them with pet owners.

“Because of the ambiguity in our law, I learned that many veterinarians chose not to talk about CBD with pet owners for fear of being disciplined,” Yeager said. “This left pet owners in a tough spot because CBD products are generally unregulated, and it would be difficult for a pet owner to know exactly what to purchase or administer without the professional advice of a veterinarian.”

Nevada voters approved medical marijuana for people by ballot initiative in 2000. Cannabis became legal for recreational use in the state on Jan. 1, 2017, following a 2016 ballot measure.

AB 101 encountered no opposition and passed the state Assembly and Senate without a single no vote, Yeager explained.

“I certainly hope that other states follow Nevada’s lead and provide reassurances to licensed veterinarians that they can administer CBD or talk about it with patients without fear of facing disciplinary proceedings,” he said. “The bill itself is fairly simple and, thus, is a good model for other states.”

Although products containing 0.3% or less THC are exempted from the federal Controlled Substances Act, the products do fall under the Federal Food, Drug, and Cosmetic Act if they are used therapeutically or included in animal food. The Food and Drug Administration considers the therapeutic use of these products to be the use of unapproved drugs.

A Simple Question

But do medical cannabinoids actually help animal patients?

It’s a deceptively simple question at the heart of an animal health concern complicated by a tangle of federal and state regulations, research challenges, and species-specific pharmacokinetics.

Dr. Dawn Boothe is a professor of veterinary physiology and pharmacology at Auburn University studying cannabis’s potential as a veterinary treatment. She sought to make sense of the issues during her presentation “Medical Cannabinoids Revisited” at AVMA Virtual Convention 2021 on Aug. 1.

The cannabis sativa plant contains more than 90 unique compounds, or cannabinoids, including CBD and THC, as well as almost 500 other terpenoids and phenylpropanoids. For several millennia, humans have used cannabinoids for pain, epilepsy, gastrointestinal disorders, and even infections.

Dr. Boothe said research interest in the therapeutic use of cannabis in the United States essentially came to a “screeching halt” in 1971 with the federal Controlled Substances Act, which listed cannabis as a Schedule 1 drug, meaning the federal government regarded cannabis as having no therapeutic properties and a high potential for abuse.

“That’s changed in the last couple of decades as, increasingly, states are paying attention to medical cannabinoids,” Dr. Boothe said. “But I do shudder to think sometimes about how much we would have learned if we had taken a different path in our reaction to cannabis.”

The federal government’s position on cannabis has somewhat softened in recent years, most notably with the 2018 Farm Bill’s removal of industrial hemp containing 0.3% or less of THC from the Controlled Substances Act. That said, the use, sale, and possession of cannabis over 0.3% THC, despite laws in many states permitting it under various circumstances, is illegal under federal law.

Making Sense of It All

The restrictions on veterinarians haven’t diminished interest among pet owners, who have available to them a veritable pharmacopeia of CBD products claiming to treat any number of animal ailments and behavioral problems.

None of the products are approved by the FDA, which, as Dr. Boothe explained, raises concerns about variability in cannabinoid concentrations, mislabeling, and contamination with harmful additives, such as fentanyl or synthetic cannabinoids.

“If you’re looking for a product that has a certificate of analysis that you can have faith in—as I would—go to the USDA (U.S. Department of Agriculture) website and look at the laboratories that the DEA (Drug Enforcement Administration) has approved as being appropriate for analysis of hemp crops,” Dr. Boothe said. “That at least can increase the level of validity for that product.”

Then there are questions about what constitutes a therapeutic dose of cannabinoid in a particular species as well as which formulations actually deliver that dose to the animal patient. There’s evidence that, in dogs, the route of CBD administration, such as in a soft capsule containing oil, may increase the oral bioavailability, according to Dr. Boothe.

“Hemp seed oil, sesame seed oil, and medium-chain triglycerides are the most common oils that are being used,” she said. “We need to see data demonstrating the differences in oral bioavailability among these different compounds.”

Cats are more challenging. “We’re going to have to have some good pharmacokinetic studies providing us information about dosing and cats,” Dr. Boothe said. “We have demonstrated that in cats there is variability in absorption, but, as in dogs, feeding will enhance that absorption.”

Dogs appear to tolerate CBD far better than THC, which was shown to cause ataxia when administered intravenously in smaller, less-concentrated doses than CBD. Dogs were also found to build a tolerance to cannabinoids over time.

Continue Reading On American Veterinary Medical Association

Recent Cannabis Articles

Get new content delivered directly to your inbox.

ALT And Grow Group Plc To Launch Liquid Medical Cannabis In Europe

ALT (Advanced Liquid Technology) has entered into an agreement with UK-based medical cannabis provider Grow Group Plc to launch and market its liquid medical cannabis products across Europe.

ALT’s proprietary, fast-acting medical cannabis product is neutral in flavor, zero-calorie, sugar-free, vegan, keto, and paleo-friendly and are designed to allow for more effective delivery in comparison to other products such as tinctures and sprays.

Advanced Liquid Technology medical cannabis products.

Medical cannabis patients will reportedly benefit from a more rapid onset time of between 5-15 minutes and more efficient absorption. ALT’s water-compatible products are made using kinetically stabilized nanoemulsions which allow cannabinoids to be effectively absorbed by the body.

ALT offers precise dosing of cannabinoids, allowing patients and clinicians to tailor treatment based on individual needs and requirements for a range of health conditions.

“We are [honored] to partner with GROW in bringing ALT’s completely differentiated brand and liquid medical cannabis technologies to the European medical markets,” said ALT CEO Robert Davis.

“After successfully launching ALT into California in December 2020, we are excited to expand internationally, our first step towards becoming a global brand. ALT’s mission is to Enhance Human Potential and we will do so, one patient at a time, through the power of our liquid cannabis platform.”

Advanced Liquid Technology medical cannabis products.

Through its new partnership with Grow Group Plc, ALT aims to have a range of EU GMP-certified medical cannabis products available to European patients through prescription by early 2022.

Grow GroupPlc CEO, Ben Langley stated: “Grow’s mission is to bring medical cannabis products to all patients who need them.

“We strive to constantly improve and innovate on our product offering. With our leading position and unique experience we are very confident that with ALT’s new mode of administration, using liquid medical cannabis, we are going to make another leap forward in providing patients with the best products and solutions for their symptom management.”

Grow Group Plc recently announced the launch of a crowdfunding campaign with Seedrs, seeking £3.2 million ($3,740,080.00 USD) of investment from “socially conscious shareholders.”

Article By Emily Ledger – Canex.com UK


Recent Cannabis Articles

Get new content delivered directly to your inbox.

5 Cannabis Stocks That Pay Dividends

NYSE Summary:

  • AbbVie Inc. (NYSE: ABBV)
  • Compass Diversified Holdings Inc. (NYSE: CODI)
  • Innovative Industrial Properties (NYSE: IIPR)
  • Scotts Miracle-Gro (NYSE: SMG)
  • Altria Group (NYSE: MO)

AbbVie Inc. (NYSE: ABBV)

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience.

Since the mid ’80s, AbbVie has marketed a drug called Marinol. Marinol is a dronabinol capsule that is chemically identical to tetrahydrocannabinol, a.k.a. THC. 

Compass Diversified Holdings Inc. (NYSE: CODI)

Compass Diversified Holdings is a publicly traded holding company (NYSE: CODI) that partners with management teams to acquire and manage North American middle market businesses. CODI is managed by Compass Group Management LLC, an active and highly successful acquirer and manager of middle market companies since 1998.

CODI’s holdings include Manitoba Harvest, a leading hemp foods group and Hemp Oil Canada.

Innovative Industrial Properties (NYSE: IIPR)

Innovative Industrial Properties, Inc. is a newly-formed, self-advised Maryland corporation focused on the acquisition, ownership and management of specialized industrial properties leased to experienced, state-licensed operators for their regulated medical-use cannabis facilities.

Scotts Miracle-Gro (NYSE: SMG)

The Scotts Miracle-Gro Company is the world’s largest marketer of branded consumer lawn and garden products. And the company took things to the next level when it purchased Hawthorne Gardening Company. This subsidiary of Scotts has long been deemed the benchmark for hydroponic growers. That’s significant because most of the hydroponic growing is dedicated to cannabis.

Altria Group (NYSE: MO)

Altria invested $1.8 billion into cannabis producer Cronos Group (NASDAQ:CRON).  Plus, more recently, they have been successfully throwing around their weight to push for cannabis legalization.

Article By EarthyRealist.com Staff

Mental Health Support Poster Download

High Quality Mental Health Support Poster To Help Those Who Need You The Most.

Help fight the stigma and become comfortable with talking about mental health with these 8 daily reminders.

Perfect for home, office, school and clinics.

This is a digital file that will download to your device. Nothing will be shipped.

Print on regular printer paper or high quality cardstock, frame and display in a central location.

Mental Health Support Poster | Mental Health Awareness | Doctors Office | Clinic | Family | Digital Download | Prints | Mental Health Awareness | Depression | Bipolar | PTSD | Schizophrenia | Schizoaffective disorder